FR2520364A1 - Medicament utilisable notamment en psychiatrie, utilisant comme principe actif un n-alkylcarbamoylphosphate de lithium - Google Patents
Medicament utilisable notamment en psychiatrie, utilisant comme principe actif un n-alkylcarbamoylphosphate de lithium Download PDFInfo
- Publication number
- FR2520364A1 FR2520364A1 FR8201348A FR8201348A FR2520364A1 FR 2520364 A1 FR2520364 A1 FR 2520364A1 FR 8201348 A FR8201348 A FR 8201348A FR 8201348 A FR8201348 A FR 8201348A FR 2520364 A1 FR2520364 A1 FR 2520364A1
- Authority
- FR
- France
- Prior art keywords
- formula
- lithium
- acid
- aggression
- phosphoric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000016571 aggressive behavior Effects 0.000 title abstract 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 title description 4
- 229910052744 lithium Inorganic materials 0.000 title description 4
- 229940125681 anticonvulsant agent Drugs 0.000 title 1
- 239000001961 anticonvulsive agent Substances 0.000 title 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 title 1
- 239000000932 sedative agent Substances 0.000 title 1
- 230000001624 sedative effect Effects 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 7
- 239000012948 isocyanate Substances 0.000 claims abstract description 6
- -1 alkyl isocyanate Chemical class 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 230000000903 blocking effect Effects 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000002641 lithium Chemical class 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 206010010904 Convulsion Diseases 0.000 abstract description 3
- 230000036461 convulsion Effects 0.000 abstract description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract description 2
- 229910003002 lithium salt Inorganic materials 0.000 abstract description 2
- 159000000002 lithium salts Chemical class 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 6
- 229910052808 lithium carbonate Inorganic materials 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3886—Acids containing the structure -C(=X)-P(=X)(XH)2 or NC-P(=X)(XH)2, (X = O, S, Se)
- C07F9/3891—Acids containing the structure -C(=X)-P(=X)(XH)2, (X = O, S, Se)
Landscapes
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8201348A FR2520364A1 (fr) | 1982-01-28 | 1982-01-28 | Medicament utilisable notamment en psychiatrie, utilisant comme principe actif un n-alkylcarbamoylphosphate de lithium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8201348A FR2520364A1 (fr) | 1982-01-28 | 1982-01-28 | Medicament utilisable notamment en psychiatrie, utilisant comme principe actif un n-alkylcarbamoylphosphate de lithium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2520364A1 true FR2520364A1 (fr) | 1983-07-29 |
| FR2520364B1 FR2520364B1 (enExample) | 1984-05-04 |
Family
ID=9270414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8201348A Granted FR2520364A1 (fr) | 1982-01-28 | 1982-01-28 | Medicament utilisable notamment en psychiatrie, utilisant comme principe actif un n-alkylcarbamoylphosphate de lithium |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2520364A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0129628A1 (fr) * | 1983-06-23 | 1985-01-02 | Marcel Richard | Médicament, utilisable notamment en psychiatrie, utilisant comme principe actif un N- alkylcarbamoylphosphate de lithium |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4063923A (en) * | 1973-07-23 | 1977-12-20 | E. I. Du Pont De Nemours And Company | Carbamoylphosphonic acid brush control agents |
| EP0021391A1 (de) * | 1979-07-03 | 1981-01-07 | Bayer Ag | Phosphonoameisensäurehydrazide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
-
1982
- 1982-01-28 FR FR8201348A patent/FR2520364A1/fr active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4063923A (en) * | 1973-07-23 | 1977-12-20 | E. I. Du Pont De Nemours And Company | Carbamoylphosphonic acid brush control agents |
| EP0021391A1 (de) * | 1979-07-03 | 1981-01-07 | Bayer Ag | Phosphonoameisensäurehydrazide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
Non-Patent Citations (1)
| Title |
|---|
| EXBK/69 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0129628A1 (fr) * | 1983-06-23 | 1985-01-02 | Marcel Richard | Médicament, utilisable notamment en psychiatrie, utilisant comme principe actif un N- alkylcarbamoylphosphate de lithium |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2520364B1 (enExample) | 1984-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1305140C (en) | Protected n -9-(1,3-dihydroxy-2-propoxymethyl) guanine derivatives | |
| EP0399856B1 (fr) | Pteridin-4 (3H)-ones, procédés de préparation et médicaments les contenant | |
| CS226181B2 (en) | Method of preparing 4-amino-5-alkylsulphonylorthoanisamide derivatives | |
| FR2489319A1 (fr) | Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant | |
| CA2515384A1 (en) | Medicament for inhibiting tumour growth | |
| US4599355A (en) | Treatment of sleep disorders | |
| CA3164224A1 (en) | Synthesis of compounds to promote hair growth | |
| CH644368A5 (en) | Hydroxylated pyrimidine derivatives, their preparation and therapeutic composition containing them | |
| FR2532647A1 (fr) | Thioesters d'acide acetylsalicylique, procede pour les preparer et compositions pharmaceutiques qui en renferment | |
| KR900006132B1 (ko) | 젬-디할로-1,8-디아미노-4-아자-옥탄 및 이의 제조방법 | |
| CA2792093C (en) | Inhibitors of intestinal apical membrane sodium/phosphate co-transport | |
| EP0280603A1 (fr) | Enantiomères de configuration absolue S de dérivés amide de l'amino-3 quinuclidine, leur procédé de préparation et leur application en thérapeutique | |
| EP0129628A1 (fr) | Médicament, utilisable notamment en psychiatrie, utilisant comme principe actif un N- alkylcarbamoylphosphate de lithium | |
| EP0133096B1 (fr) | Nouveaux dérivés de synergistines, leur préparation et les compositions pharmaceutiques qui les contiennent | |
| FR2470770A1 (fr) | Nouveaux ethers de b-imidazolylethyle de quinoleine-2 ou 4-methanols, utiles notamment comme antimicrobiens, et leur procede de preparation | |
| LU83713A1 (fr) | Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant | |
| FI84817B (fi) | Foerfarande foer framstaellning av en terapeutiskt aktiv gem-6,6-difluor-1,12-diamino-4,9-diazadodekan. | |
| US3711609A (en) | Certain furazan derivatives in therapeutic compositions and methods | |
| SU1447283A3 (ru) | Способ получени конденсированных производных @ S-триазина | |
| DE2827805A1 (de) | Alpha-vinyl-aminosaeuren und verfahren zu ihrer herstellung | |
| CA1068270A (fr) | Diamino-2,4-bromo-5 chloro-6 pyrimidines utilisables comme medicaments et procede pour leur preparation | |
| EP0347305B1 (fr) | [(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif | |
| LU81797A1 (fr) | Combinations antivirales | |
| CH658786A5 (fr) | Medicaments qui contiennent d'alpha-(n-pyrrolyl)-acides ou de leurs sels ou esters. | |
| SU507037A1 (ru) | Производные 5-(2,4-диэтиленимино)-(симм. триазинил-6) амино-1,3 диоксана, про вл ющие противоопухолевую активность , и способ их получени |